Bone Density in Voluntary Apheresis Blood Donors
- Conditions
- Bone Density
- Interventions
- Procedure: high frequency voluntary apheresis blood donation
- Registration Number
- NCT02655055
- Lead Sponsor
- Versiti
- Brief Summary
A longitudinal, randomized, controlled, single-center Phase IV clinical trial will be performed to assess changes in bone mineral density (BMD) among voluntary apheresis blood donors. The primary outcome measure will be clinically significant decline in BMD at the lumbar spine assessed by dual-energy x-ray absorptiometry (DXA).
- Detailed Description
Apheresis blood donation maximizes an individual's donation by selecting specific blood components that are used to save patient lives. Dramatic increases in the number of apheresis procedures performed each year are apparent both domestically and internationally. Apheresis requires the use of citrate anticoagulation, a substance that confers its anticoagulant effect through chelation of cations, like calcium. A small number of cross-sectional studies have reported that intermittent exposure to citrate through apheresis is associated with significant declines in donor bone mineral density (BMD). In contrast, oral potassium citrate of much lower dose has been used to treat low bone density with well-documented efficacy. The impact of citrate exposure during apheresis, either positive or negative, is important given that BMD is a significant risk factor for low trauma fracture, a problem that affects more than 2M people in the U.S. annually. It is ultimately unknown what effect repeated apheresis has on skeletal health. To address this knowledge gap, we will perform a Phase IV clinical trial of apheresis blood donors using a cross-disciplinary, multi-institutional team. As apheresis blood donation continues to affect more people, the importance of understanding the effects of repeated exposure to citrate on donor skeletal health is essential in protecting this precious community resource.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 58
- male
- eligible volunteer blood donor
- ≥ 18, and, ≤ 65 years of age at enrollment
- ≥ 1, and, ≤ 5 prior apheresis blood donation procedures
- female
- age < 18 or > 65 years at enrollment
- ineligible for whole blood donation
- BMD Z-score <(-2.0) or >(2.0) at any measurement site upon baseline assessment
- metal prosthesis at measurement site
- weight > 300 lbs (136 kg)
- previous fracture of the lumbar spine or femoral neck
- any fragility fracture, defined as a fracture resulting from a fall of standing height or less, during adulthood (specifically ≥18 years of age at the time of fracture)
- previous lumbar spinal fusion surgery
- cystic fibrosis
- emphysema
- celiac disease
- Crohn's disease
- Current or past (>1 month duration) use of medications known to affect BMD including, not limited to: (phenytoin, phenobarbital, corticosteroids)
- Current Osteoporosis Medication use including, but not limited to: (Forteo, oral biphosphonates, Reclast, Prolia, calcitonin)
- Unable or unwilling to donate high frequency apheresis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Intervention high frequency voluntary apheresis blood donation high frequency voluntary apheresis blood donation (i.e. 20 - 26 donations in one year period)
- Primary Outcome Measures
Name Time Method Dual Energy XRay Absorptiometry - Total Lumbar Spine one year The primary outcome measure is a decline in total lumbar spine bone mineral density that exceeds the technologist's least significant change (LSC) as assessed by DXA.
- Secondary Outcome Measures
Name Time Method Dual Energy XRay Absorptiometry - Femoral Neck one year A secondary outcome measure includes a decline in left or right femoral neck bone mineral density that exceeds the technologist's least significant change (LSC) as assessed by DXA.
Dual Energy XRay Absorptiometry - Total Body Composition one year Dual Energy XRay Absorptiometry - Total Hip one year A secondary outcome measure includes a decline in total hip bone mineral density that exceeds the technologist's least significant change (LSC) as assessed by DXA.
Trial Locations
- Locations (1)
BloodCenter of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States